Catalog
18 peptides, each with a one-line verdict and the evidence behind it. The badge shows the strongest tier any claim in the entry reaches, so an “Established” badge means at least one claim rests on an approval or a pivotal trial, not that everything does. How the tiers work.
4 of 18 peptides ·
- TesamorelinEstablished
GHRH analog
An FDA-approved GHRH analog that targets visceral fat.
A stabilized growth-hormone-releasing-hormone analog that raises the body's own GH pulses. It is FDA-approved to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy, backed by controlled trials — the best-evidenced GH-axis peptide here.
2 of 2 claims human-tested · 1 reference · FDA-approved
- AOD-9604Clinical
Growth-hormone fragment
The 'fat-burning fragment' the clinic couldn't confirm.
A synthetic fragment of human growth hormone marketed for lipolysis. It showed fat-metabolism activity in preclinical work, but company-run human weight-loss trials failed to beat placebo — a clean example of a great story meeting hard endpoints.
1 of 2 claims human-tested · 2 references · Research-only
- CJC-1295Clinical
Long-acting GHRH analog
One shot, a week of elevated GH and IGF-1.
A GHRH analog engineered to bind albumin (via a Drug Affinity Complex, or DAC), stretching its action from minutes to days. A human PK study showed sustained GH and IGF-1 elevation; it remains investigational and is not approved for human use. Note the DAC-free version is a different, short-acting molecule.
1 of 1 claims human-tested · 1 reference · Research-only
- IpamorelinPreclinical
Ghrelin-receptor / GH secretagogue
The selective GH pulse without the cortisol baggage.
A pentapeptide ghrelin-receptor agonist that triggers growth-hormone release with little effect on cortisol or prolactin — the selectivity that made it a research favorite. It works by a different mechanism than the GHRH analogs, and human evidence is thin; the foundational work is preclinical.
No human data yet · 1 reference · Research-only